【摘要】 目的:探讨米氮平合并认知行为疗法治疗躯体形式障碍的疗效。方法:将68例躯体形式障碍患者,随机分为研究组和对照组。研究组采用米氮平合并认知行为疗法,对照组单用米氮平治疗,疗程16周。采用症状自评量表(SCL-90)评估两组的疗效。结果:治疗16周末研究组SCL-90躯体化、抑郁、焦虑、恐怖因子分与对照组比较显著降低,差异有统计学意义(t=-2.26,-2.235,-2.15,-2.31;P<0.05)。16周末研究组总有效率85.29%,对照组总有效率61.76%,研究组有效率高于对照组(χ~2=4.836,P<0.05),差异有统计学意义。结论:米氮平合并认知行为疗法治疗躯体形式障碍优于单用米氮平治疗。更多还原

【Abstract】 Objective:To explore the clinical efficacy of cognitive behavior therapy(CBT)combined with mirtazapine in the treatment of somatoform disorder.Methods:68patients met the criteria of somatoform disorder in CCMD-3were randomly divided into study group treated with mirtazapine combined with CBT and control group treated with mirtazapine monotherapy for 16 weeks,The efficacy was assessed with symptom checklist-90(SCL-90).Results:After 16 weeks treatment,the scores of somatization,depression,anxiety,phobia factors in the study group were significantly lower than those in the control group(P<0.05).The effective rate in study group was significantly higher than that in control group at the end of the treatment(85.29% vs.61.76%;χ~2=4.836,P<0.05).Conclusion:Mirtazapine combined with CBT is better than mirtazapine monotherapy in the treatment for somatoform disorder.更多还原